Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

NCT06182891 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication dulaglutide can help protect the kidneys in adults with type 2 diabetes and kidney disease.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 300 people

Who can join Ages 18–80 · all sexes

Timeline Started 2021-10 · est. completion 2023-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06182891 ↗

Description as written by the study sponsor.

The purpose of the real-world observational prospective study is to access the renoprotective effects of dulaglutide as well as to explore corresponding mechanisms in patients with Type 2 Diabetic Nephropathy.

Treatments tested

Dulaglutide Injection also known as Other hypoglycemic agents not including GLP-1 receptor agonists Drug

Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.

Main thing measured	Evaluation of the urinary albumin-to-creatinine ratio
Sponsor	The Affiliated Hospital of Xuzhou Medical University
Conditions studied	Type 2 Diabetic Nephropathy
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06182891 ↗